In the print version of the article listed above, there is an error in four references cited in the CONCLUSIONS section. On page 2156, references 3 and 4 should be listed as 5 and 6 in the sentences “Greater improvements in glycemic control with dulaglutide were also evident in the significantly higher percentage of patients who achieved HbA1c targets of ,7.0% (53 mmol/mol) and #6.5% (48 mmol/m...

Dulaglutide is an effective Glucagon-like Peptide-1 (GLP-1) Receptor Agonist (RA) in optimizing weight and glycemic control obese patients with Type 2 Diabetes Mellitus (T2DM). The study's objective was the real-world evaluation of metabolic effect on T2DM from Southern Iraq. This study a six-month observational prospective longitudinal 185 individuals T2DM. They were initiated as add-on drug O...

While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to increase heart rate (HR), it is insufficiently recognized that the extent varies greatly between the various agonists and is affected by the assessment methods employed. Here we review published data from 24-h time-averaged HR monitoring in healthy individuals and subjects with type 2 diabetes mellitus (T2DM) treated with ...

OBJECTIVE To compare efficacy and safety of dulaglutide at doses 3.0 4.5 mg versus 1.5 in patients with type 2 diabetes inadequately controlled metformin. RESEARCH DESIGN AND METHODS Patients were randomly assigned to once-weekly mg, or for 52 weeks. The primary objective was determining superiority and/or over HbA1c reduction 36 Secondary objectives included change body weight. Two estimands a...

Dulaglutide is being extensively used for non-insulin-dependent diabetes mellitus and congestive heart failure also as an off-label weight loss aid. Due to its wide use, we had shed some light on this rare finding of normal lipase level in a patient with signs symptoms suggestive acute pancreatitis. A high index clinical suspicion pancreatitis despite should warrant low threshold radiological i...